%0 Generic
%A Puerta, JM
%A Jiménez Velasco, A
%A García, MJ
%A Molina, JR
%A Ruiz, C
%A Ferrer, C
%A Durán, MS
%A Simón, I
%A Clavero, E
%A Avellaneda, MC
%A Rosell, A
%A Ballesteros, I
%A Ramírez, S
%A Portero, MA
%A Ramírez, MJ
%A Fernández, M
%A Jiménez, M
%A Fe, R
%A Mulero, N
%A López, P
%T Efficacy and safety evaluation of nilotinib and dasatinib (2G -TKI) on first line treatment in 73 patients with CML-CP outside of clinical trials. Andalusian CML registry (RALMC)
%D 2016
%@ 0390-6078
%U http://hdl.handle.net/10668/2445
%X Even though they were approved last June 2011 to be used on first line, it is not a common procedure to begin treatment of CML-CP with 2GTKI, despite it has been demonstrated its efficacy and safety against imatinibon ENESTnd and Dasision clinical trials.
%K Dasatinib
%K Humanos
%K Mesilato de imatinib
%K Leucemia mielogenosa crónica BCR-ABL positiva
%K Pirimidinas
%K Sistema de registros
%K Andalucía
%~